Trials / Conditions / MEK Mutation
MEK Mutation
4 registered clinical trials studyying MEK Mutation — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors NCT06326411 | Nested Therapeutics, Inc | Phase 1 |
| Terminated | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors NCT07121829 | Day One Biopharmaceuticals, Inc. | Phase 1 |
| Terminated | Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations NCT04488003 | BioMed Valley Discoveries, Inc | Phase 2 |
| Available | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies NCT04566393 | xCures | — |